Fig. 19.
Ferroptosis-mediated innate immunity. (a) A schematic diagram of combinational NK cell and iron oxide NP-mediated ferroptosis cancer therapy. (b) The expression of UL16BPs and MHC class I and II expression in PC-3 prostate cancer cells after iron oxide NP treatment. (c) Tumor-size curves for each treatment group: DPBS, NK-92MI, NK-92MI + Fer, NK-92MI + Fer-aPDL1. Reproduced with permission [120]. Copyright 2022, Springer Nature.